Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Spheritech Ltd. is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity is handled by 1 distinct examiner, which represents an interaction with the USPTO for the company's current filings. This concentration allows for a focus on the technical merits of the pending application during the prosecution phase.
The busiest examiner, LOVE, Trevor M, is responsible for 1 busiest examiner pending action. Because the portfolio features 1 distinct examiner, this individual is the point of contact for all current pending matters. The prosecution is situated within 1 distinct art unit, ensuring that the examination remains within an administrative group. This creates a point of contact for all current prosecution matters handled by the office.
Managing 1 pending office action in the Biotechnology & Pharmaceuticals sector suggests an intellectual property strategy. The use of 1 distinct art unit limits the complexity of the prosecution. This environment is for maintaining arguments and responses during the examination of the company's current patent efforts. Practitioners can focus their resources on the requirements of the 1 examiner involved in the case.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOVE, TREVOR M | 1 | 43.0% | +26.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 15555811 | MICROPARTICLES | LOVE, TREVOR M | 11d overdue |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 15555811 | MICROPARTICLES | LOVE, TREVOR M | 1611 | §102DP | Final Rejection | 11d overdue | Pending | Sep 05, 2017 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial